. 2018 Feb 20;6:15. doi: 10.1186/s40425-018-0320-3

Table 2.

Overall Survival and Value of Docetaxel and Ramucirumab in 2nd-line

Nivo in 2nd-line	OS gains in days/Grade (OS/g) & HR	$4-week Costs	year-Costs	$C/LYG
Generic docetaxel (Doc) 75 mg/m2 vs. supportive care [1]	87/C HR not reported P = 0.01	$306	6 cycles: $23,868	$98,764 $197,528
Generic docetaxel (Doc) 75 mg/m2 vs. supportive care [1]	87/C HR not reported P = 0.01	$306	12 cycles: $47,736	$98,764 $197,528
Ramucirumab (Ramu) + Doc vs. Doc, squamous and non-squamous, (REVEL) [16]	42/D HR 0.86 P = 0.0235	$9333	$121,329	$1,039,963

year-Costs = 4-week Costs of $306 × 13 weeks = $3978

year-Costs of 6 cycles = $3978 × 6 = $23,868

C/LYG yearly-cost/OS gain in days × 360 days

The costs of AEs treatment (AEsTC) were not included